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Abstract
Background: Radiotherapy kills tumor-cells by inducing DNA double strand breaks (DSBs). However, the efficient repair of
tumors frequently prevents successful treatment. Therefore, identifying new practical sensitizers is an essential step towards
successful radiotherapy. In this study, we tested the new hypothesis: identifying the miRNAs to target DNA DSB repair genes
could be a new way for sensitizing tumors to ionizing radiation.
Principal Findings: Here, we chose two genes: DNA-PKcs (an essential factor for non-homologous end-joining repair) and
ATM (an important checkpoint regulator for promoting homologous recombination repair) as the targets to search their
regulating miRNAs. By combining the database search and the bench work, we picked out miR-101. We identified that miR-
101 could efficiently target DNA-PKcs and ATM via binding to the 39- UTR of DNA-PKcs or ATM mRNA. Up-regulating miR-101
efficiently reduced the protein levels of DNA-PKcs and ATM in these tumor cells and most importantly, sensitized the tumor
cells to radiation in vitro and in vivo.
Conclusions: These data demonstrate for the first time that miRNAs could be used to target DNA repair genes and thus
sensitize tumors to radiation. These results provide a new way for improving tumor radiotherapy.
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Introduction
Ionizing radiation (IR) kills cells by inducing DNA double
strand breaks (DSBs), which is one of the major cancer therapy
approaches. However, the efficient repair of DNA DSBs in the
tumors makes the tumors radioresistant, which frequently prevents
successful treatment. Therefore, identifying new practical sensitiz-
ers is an essential step towards successful radiotherapy. Mamma-
lian cells require two major DNA DSB repair pathways: non-
homologous end-joining (NHEJ) and homologous recombination
repair (HRR). The human cell lines that are deficient in the DNA-
PK catalytic subunit (DNA-PKcs) or ATM are sensitive to IR
because of the inefficient DNA DSB repair [1,2]. DNA-PKcs is a
major factor for NHEJ [3,4,5,6] and ATM, an important multi-
functional protein [7], mainly promotes HRR [8,9]. MicroRNAs
(miRNAs) represent a newly discovered class of small non-coding
RNAs with ,22 nucleotides. miRNAs bind to the 39-untranslated
region (UTR) of multiple target mRNAs and either block the
target translation or initiate the target degradation [10,11,12].
Most mammalian mRNAs are conserved targets of miRNAs [13],
and it is reasoned that identifying the miRNAs that target DNA
DSB repair genes could be a new way of sensitizing tumors to IR.
In this study, we were interested in testing the new hypothesis that
targeting DNA-PKcs and ATM with one miRNA could sensitize
tumor cells to IR.
Results and Discussion
Chose miR-101 that could bind to the 39-UTR of DNA-PKcs
and ATM
To identify a miRNA that could efficiently target both DNA-
PKcs and ATM, we combined the database (miRBase, microcosm
Targets Version 5 and miRanda) search and the manual check for
the matched sequences. As a result, we found that miR-101 is one
of the candidates because the duplex (miR-101* and miR-101)
contains the matched sequences to the 39-UTR of DNA-PKcs or
ATM mRNA (Figure 1A, B). To examine whether DNA-PKcs or
ATM is a target of miR-101, we cloned the partial 39-UTR of
DNA-PKcs or ATM mRNA (,300 bp) containing a wild type or
deleted mutant miR-101 or miR-101*-binding sequence (Figure 1A,
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the effects of miR-101 on the luciferase activity at these regions by
using a mimic miR-101 RNA that contains duplex strands of miR-
101 (including miR-101 and miR-101*). The results showed that the
luciferase activity was significantly suppressed by the reporter
containing the wild type 39-UTR of DNA-PKcs (WT) but was not
affectedbythe reporterwithoutthebindingsite:DM(Figure1C).In
addition, the luciferase activity was significantly suppressed by the
reporter containing the wild type 39-UTR of ATM (WT2) but was
not affected by the reporter containing the other wild type 39-UTR
of ATM (WT1) or the reporter without the binding site (DM1 or
DM2) (Figure 1D). These data suggest that miR-101 could suppress
the expression of DNA-PKcs or ATM through the binding
sequence at the 39-UTR of DNA-PKcs (WT) by the strand, miR-
101* or at the 39-UTR of ATM (WT2) by the strand, miR-101.
Identify DNA-PKs and ATM as the targets of miR-101
To verify whether DNA-PKcs or ATM is a target of miR-101,w e
made a lentiviral construct that contained a precursor of miR-101
(Figure S1). We used the lentiviral construct containing a pri-miR-
101 to transfect different cell lines in two different ways: 1. We
transfected one pair of human lung cancer cell lines: 95C and 95D
cells with the miR-101 vector and a vector encoding the antibiotic
marker, we selected the antibiotic resistant colonies from the
Figure 1. The effects of the putative miR-101 binding sites in the 39-UTR of DNA-PKcs or ATM on the luciferase activity. (A) The putative
miR-101* binding site in the 39-UTR of DNA-PKcs (WT). (B) The putative miR-101*o rmiR-101 binding sites in the 39-UTR of ATM (WT1, WT2). (C) The
effects of miR-101*-binding site in the 39-UTR of DNA-PKcs on the luciferase activity. 293T cells were transfected with the firefly luciferase reporter
plasmid containing partial 39-UTR of DNA-PKcs with the putative miR-101* binding site (WT) or without the binding site (DM). Luciferase activity was
assayed 48 h after transfection with the miR-101 mimic (miR-101) or without the mimic (mock), **, p,0.01. (D) The effects of miR-101*o rmiR-101-
binding sites in the 39-UTR of ATM on the luciferase activity. 293T cells were transfected with the firefly luciferase reporter plasmid containing partial
39-UTR of ATM with the putative miR-101* (WT1) or miR-101 (WT2) binding site or without the binding site (DM1, DM2). Luciferase activity was assayed
48 h after transfection with the miR-101 mimic (miR-101) or without the mimic (mock), **, p,0.01.
doi:10.1371/journal.pone.0011397.g001
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helper to infect one human GBM cell line, U87MGD cells, and
collected the cells at 48–72 h after infection. (The data derived from
the 95D cells over-expressed with miR-101 were similar to that from
the 95C cells up-expressed with miR-101, therefore, we showed one
set of results from 95C cells in this manuscript only.) The exogenous
miR-101 expressed well in both 95C-miR101 and U87MGD-
miR101 cells (Figure 2A). qRT-PCR confirmed that the exogenous
miR-101 including both strands: miR-101 and miR-101*, over-
expressed in 95C (Figure 2B) and U87MGD cells (Figure 2C). The
result from the RNase protection experiments provided additional
evidence that miR-101 over-expressed in the cells transfected with
the lentiviral vector encoding miR-101 (Figure S2). The levels of the
three PI-3 kinase like kinase (PIKK) family members: DNA-PKcs,
ATM (we predicted in this study) and mTOR (reported by another
group [14]) were dramatically decreased in both cell lines: 95C-
miR101 cells and U87MGD-miR101 cells, when compared with
that in their counterparts (Figure 2D, E). These results indicate for
the first time that, besides mTOR, DNA-PK and ATM are also
targetsofmiR-101.Theresultsconcerningtheauto-phosphorylation
level of DNA-PKcs or ATM (Figure S3) provided additional
evidence to support this conclusion.
Up-regulating miR-101 sensitizes tumor cells to radiation
To examine the effects of miR-101 on the sensitivities of theses
tumor cell lines to IR, we performed the clonogenic assay. The
Figure 2. DNA-PKs and ATM as the targets of miR-101. (A) Up-regulating miR-101 in 95C cells and U87GMD cells. The images reflect GFP signals,
which represent the infection efficiencies of the lentivirus vectors. (B) The miR-101 level (including both strands: miR-101 and miR-101*) was measured
by qRT-PCR in 95 C cells. (C) The miR-101 level (including both strands: miR-101 and miR-101*) was measured by qRT-PCR in U87GMD cells. (D) The
effects of up-regulation of miR-101 on DNA-PKcs and ATM expression in 95C cells. Ku70 was used as an internal loading control. (E) The effects of up-
regulation of miR-101 on DNA-PKcs and ATM expression in U87GMD cells. Ku70 was used as an internal loading control.
doi:10.1371/journal.pone.0011397.g002
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much more sensitive to IR than their counterparts (Figure 3A, B).
The miR-101-induced sensitization levels in these cell lines are 2.5–
5 folds at different dose points. The inhibitor of miR-101 (targeting
ATM but not DNAPKcs) or miR-101* (targeting DNA-PKcs but
not ATM) partially reversed the sensitivity of the cells over-
expressed with miR-101, and combining the two inhibitors almost
completely reversed the cell sensitivity (Figure 3C), confirming that
the sensitization effects are derived from both strands of miR-101,
which target both DNA-PKcs and ATM. miR-101 targets the
three members in the PIKK family: DNA-PKcs, ATM and
mTOR. To determine whether mTOR, similar to DNA-PK and
ATM, also contributed to the sensitization of the cells to IR, we
examined the sensitivity of the cells to IR after the mTOR level
was knocked down by a siRNA or the mTOR activity was
inhibited by rapamycin in the cells. The results showed that when
mTOR was down-regulated by siRNA (Figure S4A) or the mTOR
activity was inhibited by rapamycin in the cells (Figure S4B), the
sensitivity of the cells to IR did not change (Figure S4C, D). These
results confirm that over-expressing miR-101-induced cell radio-
sensitization is independent of mTOR. Our recent data about
another miRNA, miR-100 that could also sensitize the cells to IR
by targeting ATM (our unpublished data) provided additional
evidence to support that targeting DNA DSB repair genes could
sensitize the cells to IR-induced killing.
Up-regulation of miR-101 sensitizes human xenografts to
radiation
To study whether miR-101 could sensitize tumors to IR, we first
compared the growth rates between 95C-miR101 and 95C-vector
cells because it was recently reported that over-expression of miR-
101 could inhibit hepatocellular carcinoma development [15].
The results showed that 95C-miR101 cells did grow slowly the first
2 days after plating when compared with 95C-vector cells,
however, the two cell lines did not show apparent differences in
their growth rates after 2 days, both in an exponential style (Figure
S5). These results allowed us to use the cells developing xenograft
in mice and to examine the sensitivities of the tumors to IR in vivo.
Next, we injected 95C-miR101 or 95C-vector cells to both hind
legs of each mouse: 5 mice and 10 tumors for each type cells (10
mice in total). The tumors in the mice derived from the cells were
observed at ,10 days after the cell inoculation. We then irradiated
one hind leg of each mouse including the tumor area (5 Gy, 2
times at 72 h intervals) at 12 days after the tumor cell inoculation
and the other hind leg including the tumor area was used as the
mock-irradiation control. The results showed that without
irradiation, the size of the xenografts in mice hind legs derived
from 95C-miR101 cells was smaller than that from 95C-vector
cells at 21 days when we ended the experiment (Figure 4A,B),
indicating that miR-101 inhibited tumor growth, which is
consistent with other report [15]. More importantly, the results
Figure 3. Effects of up-regulation of miR-101 on the cell radiosensitivity. (A) The effect of up-regulation of miR-101 on 95C cell
radiosensitivity. The clonogenic assay was performed as described in Materials and Methods. Data shown are the mean and SE from three
independent experiments. (B) The effect of up-regulation of miR-101 on U87GMD cell radiosensitivity. At 72 h after infection with the lentivirus
encoding pri-miR-101, the cells were exposed to different doses. The clonogenic assay was performed as described above. Data shown are the mean
and SE from three independent experiments. (C) The effects of the miR-101 or miR-101* inhibitor on the sensitivity of the miR-101 over-expressed
U87MGD cells to IR. At 48 h after infection with the lentivirus encoding pri-miR-101, the cells were transfected with the inhibitor for an additional
36 h. The cells were exposed to 4 Gy and the clonogenic assay was performed as described above. Data shown are the mean and SE from three
independent experiments, **, p,0.01.
doi:10.1371/journal.pone.0011397.g003
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cells after receiving the radiation (5 Gy62) was much smaller than
that from 95C-vector cells after receiving the same doses of
radiation (Figure 4A, B). These results indicate that miR-101 could
sensitize tumors to radiation when miR-101 is pre-over-expressed
in tumors.
To study whether up-regulation of miR-101 by delivering
lentiviral vector encoding miR-101 to the tumor site (post tumor-
forming) could sensitize the tumor to radiation, we chose the
mouse brain xenografts derived from U87MGD cells because
brain tumor treatment depends more on the radiotherapy than
other organ tumors due to the brain-blood barrier. To avoid any
possibility that miR-101 would induce a harmful effect on the mice
born with the brain tumor, we did a literature search because one
miRNA could target many targets with different effects on the
tumors derived from different tissues [16,17,18,19]. By combining
our data (Figure 4A, B) with already published information that
miR-101 targets many oncogenes such as mTOR [14], E2H2 [20],
Mcl-1 [15,21], and FOS [15,21], and is low-expressed in many
tumors, we believe that over-expressing miR-101 will not promote
tumor growth. We then injected the tumor cells into the mice
brains. At 10 days after the tumors formed in the mice brain, we
delivered the lentiviral vector containing miR-101 to the brain
tumor site. To confirm that the lentiviral vector was delivered to
the tumor site, we sacrificed 2 mice at 72 h after the vector
delivery and removed the brain tissue for frozen or formalin-fixed
sample preparation. The results showed that the GFP signal was
limited to the tumor area (Figure 4C), indicating that the lentiviral
Figure 4. Effects of up-regulation of miR-101 on the xenograft radiosensitivity. (A) Tumor size reflected the effects of miR-101 on the
subcutaneous tumor radiosensitivity. Both hind legs of each nu/nu mouse were injected with the 95C cells with or without miR-101 up-regulated (5
mice were injected with the miR-101 up-regulated 95C cells and 5 mice were injected with the vector-transfected 95C cells, 10 mice total). The right
hind leg that born the developed tumor was exposed to IR (5 Gy62, at 72 h interval) at 12 days after the tumor cell injection and the left hind leg
that born the developed tumor was used as the mock-irradiated control. The mice were sacrificed at 21 days after the tumor cell injection and the
tumors were removed for weight comparison. (B) Tumor weight reflected the effects of miR-101 on the subcutaneous tumor radiosensitivity. The data
shown are the mean and SE: *, p,0.05; **, p,0.01; ***, p,0.001. (C) Brain tumor that developed from U87MGD glioma cells and injected with the
lentiviral vector. At 72 h after the viral vector was injected, the mice were sacrificed and the brain tissues were prepared for the pathological slides.
The GFP signals were detected by a fluorescence microscope from the frozen samples. H&E staining was used for distinguishing the tumor and
normal brain tissue from the formalin-fixed samples. (D) MRI reflected the effects of miR-101 on the brain tumor radiosensitivity. MRI scans of
individual mouse brain 18 d after intracranial inoculation of U87GMD cells. The presence of a glioma (white arrows) was detected as the bright areas
with an MRI contrast agent (Gd-DTPA). (E) Survival days reflected the effects of miR-101 on the brain tumor radiosensitivity. The data shown are the
mean and SE; *, p,0.05.
doi:10.1371/journal.pone.0011397.g004
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normal tissues. We irradiated (5 Gy) the mouse head including the
tumor area at 72 h after delivering the lentiviral vector. The
mouse head was irradiated (5 Gy) again at 72 h. We examined the
brain tumor size with magnetic resonance imaging (MRI) at 3 days
after IR (5 Gy62). The results showed that there was no apparent
difference in the tumor sizes delivered with lentiviral vector with or
without miR-101 (Figure 4D), however, the tumor size with
lentiviral vector encoding miR-101 plus IR (5 Gy62) was smaller
than that with lentiviral vector alone plus IR (Figure 4D). The
survival results showed that the mice dying at ,20 days after the
tumor cells were injected in their brains without IR (Figure 4E)
and the mice with the lentiviral vector or the vector encoding miR-
101 showed a similar survival time (Figure 4E). These data provide
additional evidence that the lentiviral vector did not stimulate the
tumor growth. IR (5 Gy62, at 72 h interval) extended the mice’
survival days to ,25 days (Figure 4E), indicating that IR delayed
the tumor growth. Although delivering the lentiviral vector alone
at 72 h before IR did not extend the mice’ survival days
(Figure 4E), delivering the lentiviral vector containing miR-101
at 72 h before IR clearly extended the mice’ survival days to ,30
days (Figure 4E). The body weight of these mice at 2 days after IR
provided additional evidence that demonstrated the radio-
sensitizing effects of miR-101 on the tumors (Figure S6). These
results strongly support that miR-101 could be delivered to the
tumor site and sensitize the tumor to radiation.
The field of small RNAs is rapidly developing toward in vivo
delivery for therapeutic purposes. Although it was reported that
miRNAs could serve as potential agents and alter resistance to
cytotoxic anticancer therapy [22]; until now, there is no report
that uses one miRNA to directly target the DNA repair gene and
sensitize tumors to radiation or chemotherapy. Our data in this
study demonstrate for the first time the feasibility. The biggest
advantage for choosing miRNAs as a therapeutic tool is that one
miRNA could target multi-targets with less degradation due to the
Drosha-Dicer modification process in the cell. Advanced molec-
ular therapy aimed at up-modulating the level of a given miRNA
in the mouse model has been reported with a different viral vector
[19]. We believe that our data demonstrate that CHOSING THE
INTERESTING GENES AND THEN IDENTIFING THE
MATCHED MIRNAS TO TARGET THE GENES provides a
new strategy for future miRNA-therapy.
Materials and Methods
Ethics Statement
All the mouse work was followed using the approved animal
protocol according to the guidelines of Emory University
Institutional Animal Care and Use Committee. The protocol
number is 004-2010 and the title of the protocol is ‘‘Study the
effects of miRNA on sensitizing malignant glioma cells to radiation
therapy’’. All mice were handled in strict accordance with good
animal practice as defined by the relevant national and/or local
animal welfare bodies.
Plasmids construction
To construct a plasmid expressing miR-101, we amplified pri-
miR-101 using the genomic DNA from a healthy blood donor as
we previously did for the miR-145 construction [23] only with the
different primers (Supplementary Table S1). The amplified
fragment was first cloned into a PCR cloning vector and
subsequently cloned into a lentiviral vector: pCDHCMV-MCS-
EF1-copGFP (System Biosciences) at the EcoR1 and NotI sites.
Expression of miR-101 was verified by TaqMan real-time
RT-PCR. The luciferase-UTR reporter plasmid that contains
the DNA-PKcs or ATM 39-UTR carrying a putative miR-101 or
miR-101* binding site (WT for DNA-PKcs, WT1 or WT2 for
ATM) or a deleted mutant without the miR-101 or miR-101*
binding site (DM for DNA-PKcs, DM1 or DM2 for ATM) was
constructed as follows: Briefly, the complementary oligonucleo-
tides (Table S1) for each selected regions were hybridized to form
double-stranded DNA and inserted into pMIR-ReporterTM
firefly luciferase vector (Applied Biosystems, Foster City, CA,
USA). All constructs were confirmed by sequencing.
PCR/RT-PCR and quantitative RT-PCR (qRT-PCR)
PCRs were performed to amplify pri-microRNA sequences or
the DNA-PKcs or ATM 39-UTR sequence according to the
standard three-step procedure. For RT-PCR, total RNA was
isolated by using a Trizol reagent (Invitrogen) and the small RNA
was isolated by using a miRNeasy Mini Kit (Qiagen). RNA (1 mg)
was used to synthesize cDNA by using a TaqManH MicroRNA
Reverse Transcription Kit (Applied Biosystems). qRT-PCR was
performed in triplicate with a TaqManH Universal PCR Master
Mix and a specific TaqManH MicroRNA assay (Applied
Biosystems) on an ABI PRISMH 7000 Sequence Detection System
(Applied Biosystems). Samples were normalized to RNU48 RNA,
and relatively quantified using a 2
2DDC
T method [24].
RNase protection assay
The RNA probes were constructed by PCR and in vitro
transcription. Briefly, forward and reverse primers that include a
T7 promoter upstream to a mature miRNA sequence (hsa-miR-101
or RNU48) with 10 over-lapping nucleotides were designed
(Supplementary information Table S1). Amplified PCR was
purified by using a QIAquick spin column (Qiagen, Valencia,
CA, USA) and proceeded with a Megashortscript
TM kit (Ambion,
Austin, TX, USA) according to the manufacturer’s protocol. The
RNA probes were hybridized to the total RNA of U87MGD cells
infected with the lentiviral vector or the vector encoding miR-101
by using a mirVana
TM miRNA detection kit (Ambion) according
to the manufacturer’s instructions. Gel was exposed directly to a
phosphor screen overnight and the signals were detected by using
a Typhoon
TM 9210 (GE, Bio-Sciences, Piscataway, NJ, USA).
Cell lines and transfection/transduction
The lung cancer cell lines, 95C and 95D were obtained from
Dr. Yinglin Lu’s laboratory at the 301 Hospital, Beijing China
[25]. 293FT cells were purchased from the American Type
Culture Collection. The human GMB cell line, U87MGD, was
obtained from Dr. Van Meir’s laboratory at Emory University,
Atlanta, USA [26]. 95C or 95D cells were directly co-transfected
with the lentiviral vector-miR101 and the pCDHCMV-MCS-EF1
plasmid encoding a puromycin (Puro) antibiotic selective marker
(System Biosciences), at a ratio of 20:1 by using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions.
The Puro resistant colonies were selected and the miR-101 levels
were measured by qRT-PCR. The glioma cell lines: U87MG or
M059K cells were transduced by the packaged lentivirus. Briefly,
approximately 2610
6 293FT cells were seeded in a 100 mm dish
overnight. The lentiviral vector-miR-101 or lentiviral vector alone
(2 mg) and pPACKH1 Packaging Plasmid Mix (10 mg) (System
Biosciences, Mountain View, CA, USA) were formed into a
complex with Lipofectamine
TM 2000 and transfected to the
293FT cells. The culture medium containing the packaged viruses
was harvested at 48 hr after transfection and spun at 4uC,
3000 rpm for 10 min. The supernatant was collected and
polybrene was added to the final concentration 8 mg/ml. The
New Radiosensitizer for Tumor
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dish with 5 ml of medium. The transduced cells were harvested
after 72–96 hr post-infection for further experiments. For siRNA
and miRNA inhibitor transfection, Lipofectamine
TM 2000 was
mixed with either 100 nM siRNA of ATM, Dicer (Santa Cruz
Biotech Inc), hsa-miR-101 inhibitor, or hsa-miR-101* inhibitor
(Thermo Fisher Scientist Inc) as previously described [27]. Cells
were harvested at 36 hr after transfection for further experiments.
Antibodies and reagents
The anitibody against DNA-PKcs (MS-370-P1) was purchased
from Thermo Fisher Scientific Inc. The antibodies against ATM
(2837S), mTOR (2927), p70 S6 kinase (9202) and phospho-p70 S6
kinase at Thr389 (9202) were purchased from Cell Signaling. The
antibody against autophosphorylated DNA-PKcs (S2056) was
kindly provided by Dr. Benjamin P. C. Chen at the UT
Southwestern Medical Center [28]. The antibody against
autophosphorylated ATM (S1981) was purchased from Rockland
Inc. The antibody against Ku70 (SC-17789) was purchased from
Santa Cruz Biotech Inc.
Luciferase assay
293FT cells were transfected with the appropriate plasmids with
or without 100 nM hsa-miR-101 mimics (Thermo Fisher Scientific)
in 48-well plates. The cells were harvested 48 h after transfection,
the cells were then lysed with a luciferase assay kit (Promega)
according to the manufacturer’s protocol and were measured on a
luminescence microplate reader LUMIstar Galaxy (BMG lab-
technologies). b-galactosidase or renilla luciferase was used for
normalization.
Cell radiosensitivity assay
Cell sensitivity to radiation was determined by the loss of
colony-forming ability. Briefly, the cells were irradiated by using
an x-ray machine (X-RAD 320, N. Branford, CT, USA) at
320 kV, 10 mA, with a filtration of 2-mm aluminum. The dose
rate was 2 Gy/min. After IR, the cells were collected and plated,
aiming at a density of 20–100 colonies per dish. Two replicate
dishes were prepared for each datum point, and cells were
incubated for 2 weeks. Colonies were stained with crystal violet
(100% methanol solution).
Xenograft tumor radiosensitivity studies
For subcutaneous xenografts, briefly, both hind legs of each nu/
nu mouse were subcutaneously injected with 2610
6 95C cells
transfected with vector alone or with the vector encoding miR-101,
5 mice for each group. Ten days later, when the xenografts formed
in both hind legs, the right hind leg of each mouse was exposed to
x-ray (5 Gy) and the left one was used as the mock-irradiation
control. The right hind legs were irradiated with 5 Gy again at
72 h. The radiation was performed by the same x-ray machine
with a different filter (1.5 mm aluminum, 0.8 mm tin and
0.25 mm copper), at a dose rate of 1 Gy/min. The mice were
sacrificed at 21 days after the tumor cell inoculation and the
tumors were removed and weighted. For brain xenografts, briefly,
2.5610
5 glioma cells were stereotactically injected into the brains
of athymic nu/nu mice. A 2-mm drill was then used to make a
burr hole 2 mm to the right and 1 mm anterior of the bregma of
the skull. A 23-gauge Hamilton syringe was advanced 2.5 mm
deep, and then retracted 0.5 mm for implanting 5 mL of tumor cell
suspension. Ten days later, the mouse brain tumor site was
injected with 5 mL of lentiviral vector (pCDH-CMV-MCS-EF1-
copGFP) with or without miR-101. At 72 h after the lentiviral
vector injection, the mouse head including the brain tumor area
was exposed to x-ray (5 Gy), and irradiation were repeated with
5 Gy at 72 h. The body weight was determined at 18 days after
the tumor cell inoculation.
Magnetic resonance imaging (MRI)
Magnetic resonance imaging (MRI) was performed on a 4.7T
MRI scanner (Philips Intera) using a small volume coil (4 cm
diameter). Matrix of 256 (reconstructed to 512) and 0.5 or 1 mm
slice thickness were used to collect a set of axial images (typically
15–20 slices). T2 weighted fast spin echo imaging using parameters
of TR/TE=5000/56ms and T1 weighted spin echo imaging
using TR/TE=400/11ms were applied. The average number of
signals was typically set at 4 to obtain sufficient signal to noise
ratio. An MRI contrast agent, gadolinium diethylenetriamine-
pentaacetic acid (Gd-DTPA), was administrated (i.v.) at a dose of
0.2 mmol/kg and followed by a post-contrast T1 weighted spin
echo imaging by using the parameter above.
Statistical analysis
Statistical analysis of data was done using the Student’s t test.
Differences with p,0.05 are considered significant.
Supporting Information
Table S1 Primer information.
Found at: doi:10.1371/journal.pone.0011397.s001 (0.05 MB
DOC)
Figure S1 The plasmid map. The pri-miR-101 using genomic
DNA from a healthy blood donor as a template was amplified.
The PCR reactions were performed with the specific primers
(Table S1) by using a high fidelity Phusion enzyme (New England
Biolabs). The amplified fragment was first cloned into a PCR
cloning vector and subsequently cloned into pCDHCMV-MCS-
EF1-copGFP at the EcoRI and NotI sites.
Found at: doi:10.1371/journal.pone.0011397.s002 (1.27 MB TIF)
Figure S2 Different expression of miR-101. Different expression
of miR-101 in U87MGD cells with or without vector infection was
detected by using an RNase protection assay. 1, 2: U87MGD cells
without infection; 3, 4: U87MGD cells infected with the lentiviral
vector encoding miR-101; 5, 6: U87MGD cells infected with the
lentiviral vector alone. Lanes 1, 3, 5: the RNAs were amplified by
PCR with the RNU48 primers, and the RNU48 RNA was used as
the internal loading controls; 2, 4, 6: the RNAs were amplified by
PCR with the miR-101 primers.
Found at: doi:10.1371/journal.pone.0011397.s003 (0.69 MB TIF)
Figure S3 Effects of miR-101 on the autophosphorylation of
ATM or DNA-PKcs. 95C cells transfected with the vector alone or
encoding miR-101 were exposed to ionizing radiation (4 Gy), and
were returned to the 37uC incubator. At 1 h after radiation, the
cells were collected for preparing whole cell lyses. The autopho-
sphorylational signals of ATM S1981 (p-ATM) or DNA-PKcs
S2056 (p-DNA-PKcs) were detected by Western blot. Ku70 was
used as an internal loading control.
Found at: doi:10.1371/journal.pone.0011397.s004 (0.80 MB TIF)
Figure S4 Effects of mTOR on cell radiosensitivity. (A) 95C cells
were transfected with mTOR siRNA (100 nM) or control RNA.
The cells were collected at 48 h after transfection and the protein
levels were detected by Western blot. Ku70 was used as an internal
loading control. (B) The cells were treated with rapamycin 20 nM
for 309 in a serum free condition and were added with equal
medium containing 20% calf serum for 3 h. The cells were
New Radiosensitizer for Tumor
PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11397collected and the protein levels were detected by Western blot.
Ku70 was used as an internal loading control. (C) The cells were
irradiated at 48 h after transfection with the RNA and the
clonogenic assay was performed. The data represent mean and SE
of three independent experiments. (D) The cells were treated with
rapamycin as described in (B) and were irradiated with different
doses. The clonogenic assay was performed. The data represent
mean and SE of three independent experiments.
Found at: doi:10.1371/journal.pone.0011397.s005 (1.50 MB TIF)
Figure S5 Effects of miR-101 on the cell growth. 95C cells
transfected with the vector alone or encoding miR-101 were plated
into 60 mm dishes with 20,000 cells, 5 dishes for each group. The
cells were collected and counted with a Coulter Counter. The data
represent mean and SE of three independent experiments.
Found at: doi:10.1371/journal.pone.0011397.s006 (1.07 MB TIF)
Figure S6 Effects of miR-101 on the body weight of the mice
born with the brain tumor derived from U87MGD cells. The head
of the mice were injected with U87MGD cells. The mice were
divided into 6 groups (6 mice/group): 1. no-treatment; 2. the brain
tumor site was injected with lentiviral vector alone 10 days after
tumor cell implantation, 3. the brain tumor site was injected with
lentiviral vector encoding miR-101; 4. the head of the mice born
with the tumor was irradiated (5 Gy62, at 72 h interval) at 10
days after the tumor cell inoculation; 5. at 72 h after the vector
without miR-101 injection, the head of the mice born with the
tumor was irradiated (5 Gy62); 6. at 72 h after the vector with
miR-101 injection, the head of the mice born with the tumor was
irradiated (5 Gy62). The mice were weighed at 18 days after the
tumor cell inoculation. The data represent mean and SE of six
mice for each group: *, p,0.05 and **, p,0.01.
Found at: doi:10.1371/journal.pone.0011397.s007 (1.17 MB TIF)
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